AI and emerging clinical trends are reshaping the R&D landscape at unprecedented speed. This panel discussion will explore shifting scientific priorities, data-driven decision-making, and the evolution of trial design trial design, offering clear perspective into how the next generation of therapies will be discovered, developed, and delivered.
Monday, May 4, 16:30 - 17:15, room Delhi
| Name | Position | Institution |
|---|---|---|
| Daniel Chancellor | VP of Thought Leadership | Norstella |
| Name | Position | Institution |
|---|---|---|
| Martin Svorc | Director, Neurology & Immunology, Business Development & AI Strategy and Enablement Lead | Merck |
| Benjamin August | Senior Director, Search & Evaluation – Research & Technologies | Daiichi Sankyo |
| Michael Pitzner | Group General Counsel, Senior Vice President, Legal and Business Development | Molecular Partners |
| Samir Ounzain | CEO and Co-Founder | HAYA Therapeutics |
Citeline, a Norstella company, provides a comprehensive suite of business intelligence solutions that help health science professionals connect treatments to patients. Our patient‑focused data and analytics support clinical, commercial, and regulatory decision‑making an create real‑world opportunities for growth. Our global analysts, journalists, and consultants track the pharmaceutical, biomedical, and medtech industries, delivering expert insights across key diseases, clinical trials, drug R&D and approvals, and market forecasts.
